{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:33:05Z","timestamp":1761586385008,"version":"build-2065373602"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There are few epidemiologic studies of the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) among pediatric populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      To estimate the cross-sectional prevalence of MASH in the pediatric (&lt;18 years) populations of\n                      <jats:underline>Merative<\/jats:underline>\n                      <jats:sup>\n                        <jats:underline>TM<\/jats:underline>\n                      <\/jats:sup>\n                      MarketScan\u00ae Commercial Database (Commercial) and\n                      <jats:underline>Merative<\/jats:underline>\n                      <jats:sup>\n                        <jats:underline>TM<\/jats:underline>\n                      <\/jats:sup>\n                      MarketScan\u00ae Multi-State Medicaid Database (Medicaid).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pediatric patients with \u22651 medical encounter from 1\/1\/2020 to 12\/31\/2020 and \u22656 months of continuous enrollment before the most recent medical encounter were included. MASH was confirmed by an ICD-10-CM diagnosis code for MASH (K75.81) in the medical history since 1\/1\/2016.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,476 and 410 pediatric MASH patients were identified in Medicaid and Commercial databases respectively, with a prevalence of 0.036% (95% confidence interval (CI): 0.034%, 0.038%) in Medicaid, as compared to 0.011% (95% CI: 0.010%, 0.012%) in Commercial. Prevalence of MASH increased by age. MASH was more prevalent in those who were male, obese, had T2D, and had metabolic syndrome. Among all pediatric MASH patients, the majority were \u226510 years old, male, and obese.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>MASH is more prevalent among pediatric patients with comorbid conditions such as metabolic syndrome, obesity, and T2D, which appears to be similar to young adults. Rising prevalence of childhood obesity and related comorbid conditions, and the progressive nature of MASH, make this an area of increasing medical need. Prescreening MASH among high-risk patients with these comorbidities is needed for target intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0334971","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:29:45Z","timestamp":1761586185000},"page":"e0334971","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and characteristics of metabolic dysfunction-associated steatohepatitis among pediatric patients in the MarketScan Databases"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7085-7072","authenticated-orcid":true,"given":"Kennedy M.","family":"Peter-Marske","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongtong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel S.","family":"Engel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"2","key":"pone.0334971.ref001","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications","volume":"51","author":"E Fabbrini","year":"2010","journal-title":"Hepatology"},{"issue":"8","key":"pone.0334971.ref002","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cgh.2012.03.011","article-title":"Features, diagnosis, and treatment of nonalcoholic fatty liver disease","volume":"10","author":"DM Torres","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0334971.ref003","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4254\/wjh.v6.i5.274","article-title":"Gender and racial differences in nonalcoholic fatty liver disease","volume":"6","author":"J-J Pan","year":"2014","journal-title":"World J Hepatol"},{"key":"pone.0334971.ref004","volume-title":"Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment Guidance for Industry","author":"Research FaDACfDEa","year":"December 2018"},{"issue":"3","key":"pone.0334971.ref005","article-title":"An Observational Data Meta-analysis on the Differences in Prevalence and Risk Factors Between MAFLD vs NAFLD","volume":"21","author":"GEH Lim","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"pone.0334971.ref006","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"ZM Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"pone.0334971.ref007","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"C Estes","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"pone.0334971.ref008","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States","volume":"148","author":"RJ Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"31","key":"pone.0334971.ref009","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011518","article-title":"Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016","volume":"97","author":"P Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"pone.0334971.ref010","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances","volume":"113","author":"M Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"pone.0334971.ref011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","article-title":"NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)","volume":"64","author":"MB Vos","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"pone.0334971.ref012","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jhep.2019.06.023","article-title":"Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease","volume":"71","author":"V Nobili","year":"2019","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0334971.ref013","first-page":"48","article-title":"Pediatric Non-Alcoholic Fatty Liver Disease","volume":"4","author":"H Bush","year":"2017","journal-title":"Children (Basel)"},{"key":"pone.0334971.ref014","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity","volume":"207","author":"EL Yu","year":"2019","journal-title":"J Pediatr"},{"issue":"4","key":"pone.0334971.ref015","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/HEP.0000000000000383","article-title":"Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019","volume":"78","author":"P Hartmann","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"pone.0334971.ref016","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"Liver biopsy","volume":"49","author":"DC Rockey","year":"2009","journal-title":"Hepatology"},{"issue":"6","key":"pone.0334971.ref017","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"N Chalasani","year":"2012","journal-title":"Hepatology"},{"issue":"4","key":"pone.0334971.ref018","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","article-title":"Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease","volume":"157","author":"JB Schwimmer","year":"2019","journal-title":"Gastroenterology"},{"issue":"10","key":"pone.0334971.ref019","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/apt.12518","article-title":"Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease","volume":"38","author":"JB Schwimmer","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0334971.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2013.10.071","article-title":"Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels","volume":"164","author":"JP Molleston","year":"2014","journal-title":"J Pediatr"},{"issue":"6","key":"pone.0334971.ref021","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis","volume":"69","author":"Z Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"pone.0334971.ref022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpeds.2005.07.020","article-title":"Underdiagnosis of pediatric obesity and underscreening for fatty liver disease and metabolic syndrome by pediatricians and pediatric subspecialists","volume":"147","author":"MR Riley","year":"2005","journal-title":"J Pediatr"},{"issue":"4","key":"pone.0334971.ref023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jpeds.2009.06.014","article-title":"Pediatric Nonalcoholic Fatty Liver Disease in 2009","volume":"155","author":"A Alisi","year":"2009","journal-title":"The Journal of Pediatrics"},{"key":"pone.0334971.ref024","unstructured":"IBM. IBM MarketScan Research Databases for Life Sciences Researchers. 2018. https:\/\/www.ibm.com\/downloads\/cas\/0NKLE57Y"},{"key":"pone.0334971.ref025","unstructured":"Services C f MM. Medicaid data sources - general information. 2021. https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Computer-Data-and-Systems\/MedicaidDataSourcesGenInfo"},{"issue":"4","key":"pone.0334971.ref026","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1542\/peds.2006-1212","article-title":"Prevalence of fatty liver in children and adolescents","volume":"118","author":"JB Schwimmer","year":"2006","journal-title":"Pediatrics"},{"key":"pone.0334971.ref027","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2018.04.047","article-title":"Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study","volume":"200","author":"DM Fernandes","year":"2018","journal-title":"J Pediatr"},{"key":"pone.0334971.ref028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2018.02.038","article-title":"Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease","volume":"198","author":"KE Harlow","year":"2018","journal-title":"J Pediatr"},{"issue":"3","key":"pone.0334971.ref029","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2017.02.030","article-title":"In children with nonalcoholic fatty liver disease, zone 1 steatosis is associated with advanced fibrosis","volume":"16","author":"JA Africa","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"pone.0334971.ref030","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"JB Schwimmer","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"pone.0334971.ref031","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13098-021-00665-0","article-title":"Burden of non-alcoholic steatohepatitis among children with type 2 diabetes mellitus","volume":"13","author":"L Parlett","year":"2021","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"pone.0334971.ref032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dci20-0053","article-title":"Social Determinants of Health and Diabetes: A Scientific Review","volume":"44","author":"F Hill-Briggs","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"pone.0334971.ref033","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s13679-015-0185-4","article-title":"Socioeconomic Status, Risk of Obesity, and the Importance of Albert J. Stunkard","volume":"5","author":"G Pavela","year":"2016","journal-title":"Curr Obes Rep"},{"key":"pone.0334971.ref034","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvac150.049","article-title":"PSUN121 Nonalcoholic Steatohepatitis (NASH), Race\/Ethnicity, and Gender in Adult US Population of NHANES 17-18","volume":"6","author":"T Friedman","year":"2022","journal-title":"Journal of the Endocrine Society"},{"issue":"3","key":"pone.0334971.ref035","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(19)30419-4","article-title":"Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study","volume":"5","author":"KWM Abeysekera","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"pone.0334971.ref036","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/hep4.1689","article-title":"Patient Determinants for Histologic Diagnosis of NAFLD in the Real World: A TARGET-NASH Study","volume":"5","author":"AS Barritt","year":"2021","journal-title":"Hepatol Commun"},{"issue":"3","key":"pone.0334971.ref037","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1053\/j.sempedsurg.2009.04.004","article-title":"Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery","volume":"18","author":"PE Pardee","year":"2009","journal-title":"Semin Pediatr Surg"},{"issue":"2","key":"pone.0334971.ref038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/jcpt.12379","article-title":"Metformin prescription patterns among US adolescents aged 10-19 years: 2009-2013","volume":"41","author":"T Wang","year":"2016","journal-title":"J Clin Pharm Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334971","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:29:52Z","timestamp":1761586192000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0334971"}},"subtitle":[],"editor":[{"given":"Mahmoud M","family":"Werfalli","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":38,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0334971","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}